Infographic: the port delivery system with ranibizumab for neovascular age-related macular degeneration: ladder trial

Access through your institution Buy or subscribe REFERENCE TO ORIGINAL ARTICLE: Campochiaro, P. A., Marcus, D. M., Awh, C.C. et al. The port delivery system with ranibizumab for neovascular

age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology, 126(8), 1141–1154. This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 18 print issues and online access $259.00 per year only $14.39 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * UCL Institute of Ophthalmology, London, UK Ishani Barai, 

Sobha Sivaprasad & Christin Henein Authors * Ishani Barai View author publications You can also search for this author inPubMed Google Scholar * Sobha Sivaprasad View author publications

You can also search for this author inPubMed Google Scholar * Christin Henein View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS All authors

equally contributed to the conceptualisation and creation of the visual abstract. CORRESPONDING AUTHOR Correspondence to Christin Henein. ETHICS DECLARATIONS COMPETING INTERESTS SS reported

receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos,

Ocular Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, Sanofi. SS is Editor in Chief of Eye. IB & CH declare no conflict of interest. ADDITIONAL INFORMATION

PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Barai, I., Sivaprasad, S. & Henein, C. Infographic: The port delivery system with ranibizumab for neovascular age-related macular degeneration: LADDER

trial. _Eye_ 39 (Suppl 1), 126–128 (2025). https://doi.org/10.1038/s41433-024-03337-1 Download citation * Received: 18 March 2024 * Revised: 06 August 2024 * Accepted: 05 September 2024 *

Published: 18 September 2024 * Issue Date: February 2025 * DOI: https://doi.org/10.1038/s41433-024-03337-1 SHARE THIS ARTICLE Anyone you share the following link with will be able to read

this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative